Developer docs
API playgroundTry for free, no card

Search company profiles

PCI Pharma Services

Full company profile

uuid00533x1

Namestring
PCI Pharma Services
Legal namestring
Packaging Coordinators, Inc.
Websiteurl
pci.com
Company typeenum
Private
Founded yearint
1972
Descriptiontext

PCI Pharma Services is a privately held global Contract Development and Manufacturing Organization (CDMO) founded in 1972 and headquartered in Philadelphia, Pennsylvania. Operating under the legal entity Packaging Coordinators, Inc., the company provides integrated end-to-end drug development, manufacturing, and packaging services to pharmaceutical and biotechnology companies and clinical trial sponsors. Its service portfolio spans sterile and non-sterile drug development, lyophilization, fill-finish, prefilled syringe services, high-potency compound handling, biologics packaging, clinical trial supply chain management, cold chain logistics, commercial packaging, and advanced drug-device combination product assembly.

The company operates 38 GMP-compliant facilities across 30 sites in seven countries (United States, Canada, United Kingdom, Ireland, Germany, Spain, and Australia), supported by more than 8,000 employees. PCI's technology layer centers on the pci|bridge™ digital supply chain platform, which provides clients with real-time visibility into project status, inventory, documentation, and Qualified Person lot release workflows, integrated with DocuSign and Smartsheet. The platform is anchored by validated quality systems including MasterControl, LIMS, and electronic batch records. Supporting offerings include clinicalSMART™ for clinical supply project management, Activ-Blister™ for clinical trial blister packaging, and SpeedSolutions™ for accelerated commercialization.

PCI generates revenue through professional services engagements — long-term development, manufacturing, and packaging contracts with pharma and biotech clients — priced on a quote/contract basis per project. Go-to-market is direct enterprise field sales targeting pharmaceutical and biotech decision-makers, supported by industry conference participation, content marketing, and ESG-driven thought leadership. The company has grown substantially through acquisitions, completing five notable deals between 2017 and 2023 (LSNE, Penn Pharmaceutical Services, Sherpa Clinical Packaging, Pharmaceutical Packaging Professionals, and Millmount Healthcare), and has been recognized with multiple industry awards including 2025 CDMO Leadership Awards for Small Molecule and Biologics categories and consecutive EcoVadis Bronze Medals for sustainability performance.

Short descriptiontext

PCI Pharma Services is a privately held global CDMO providing integrated end-to-end drug development, manufacturing, and packaging services to pharmaceutical and biotechnology companies across 38 GMP facilities in seven countries, supported by the pci|bridge™ digital supply chain platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersPhiladelphia, PA, United States
HQ citystring
Philadelphia, PA
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices15 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, clinical trial supply services, sterile fill-finish, pharmaceutical packaging services, drug-device combination products
Industry4 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical CDMO Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Development & Manufacturing Services
TypeProfessional Services
Description

Comprehensive drug development and manufacturing services including sterile and non-sterile manufacturing, lyophilization, fill-finish, prefilled syringe services, high-potency drug development and manufacturing, and oral targeted therapies.

pci.com
2Clinical Trial Services
TypeProfessional Services
Description

End-to-end clinical trial supply services including temperature controlled packaging, cold chain logistics, clinical storage and distribution, packaging design and development, and returns management.

pci.com
3Commercial Packaging Technology
TypeProfessional Services
Description

Commercial packaging services for both sterile and non-sterile products including standard and specialty dosage forms, serialization, compliance packaging, and launch support.

pci.com
4Advanced Drug Delivery & Drug-Device Combination Products
TypeProfessional Services
Description

Specialized services for drug-device combination products including prefilled syringes, advanced delivery systems, and combination product assembly and packaging.

pci.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1clinicalSMART
Description

Clinical supply project management solution for clinical trials

pci.com
+3 more records
Core offering1 text field

PCI Pharma Services is a global contract development and manufacturing organization (CDMO) providing integrated end-to-end drug development, manufacturing, and packaging solutions for pharmaceutical and biotech clients. Services span sterile and non-sterile development and manufacturing, clinical trial supply chain services, commercial packaging technology, advanced drug delivery, and drug-device combination products, delivered through 38 GMP facilities across 7 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • More than 90 successful product launches per year
+2 more records
Product overview1 text field

PCI Pharma Services is a global Contract Development and Manufacturing Organization (CDMO) providing integrated end-to-end drug development, manufacturing, and packaging solutions. The company operates two primary service categories: Sterile Services and Non-Sterile Services, each encompassing Development & Manufacturing, Clinical Trial Services, and Commercial Packaging Technology. The portfolio is anchored by the pci | bridge™ digital supply chain management platform, which provides clients with real-time visibility and integrates with DocuSign and Smartsheet. Supporting offerings include clinicalSMART™ for clinical supply project management, Activ-Blister™ Solutions for patient compliance packaging, and SpeedSolutions™ for accelerated commercialization. PCI also employs validated systems including MasterControl and LIMS within its digital quality ecosystem to ensure compliance and operational precision.

Product and service6 records
1Sterile Services
CategoryPharmaceutical CDMO Services
Description

Integrated sterile pharmaceutical CDMO services spanning drug development and manufacturing, clinical trial services, advanced drug delivery, and commercial packaging technology for sterile pharmaceutical products. Capabilities include sterile fill-finish, lyophilization (cycle development, bulk, and fill-finish), prefilled syringe services, complex formulations, and drug-device combination product assembly. Targeted at pharmaceutical and biotech clients requiring sterile manufacturing and packaging for injectable, biologic, and high-potency products.

2Non-Sterile Services
CategoryPharmaceutical CDMO Services
Description

Integrated non-sterile pharmaceutical CDMO services spanning drug development and manufacturing, clinical trial services, and commercial packaging technology for non-sterile pharmaceutical products. Targeted at pharmaceutical and biotech clients requiring oral solid dose, topical, and other non-sterile manufacturing and packaging services.

3SpeedSolutions™
CategoryPharmaceutical CDMO Services
Description

Integrated suite of speed-to-market solutions designed to accelerate drug development and commercialization timelines for pharmaceutical and biotech clients. Brings together PCI's capabilities across development, manufacturing, clinical supply, and commercial packaging under a unified accelerated timeline approach.

4pci | bridge™ Digital Supply Chain Platform
CategoryDigital Platform
Description

Client-facing digital supply chain management platform connecting clients to critical operational data with real-time visibility into project status, inventory movement, and documentation workflows across clinical development through commercial launch. Features include customizable KPI dashboards, real-time inventory data, configurable reports, secure document sharing via DocuSign, automated QP lot release workflows, protocol spend tracking, and commercial forecast submission. Sold as part of PCI's CDMO service engagement for pharmaceutical and biotech clients.

5clinicalSMART™ Clinical Supply Project Management
CategoryClinical Trial Services
Description

Clinical supply project management service solution for tracking and managing clinical trial logistics, packaging, and distribution activities. Targeted at pharmaceutical and biotech sponsors running clinical trials who require integrated supply chain visibility and project coordination.

6Activ-Blister™ Solutions
CategoryClinical Trial Services
Description

Specialized blister packaging solutions for clinical trials, designed for patient compliance and adherence packaging. Targeted at pharmaceutical and biotech sponsors running clinical trials requiring patient-centric packaging to support medication adherence.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierSignificantTypeStrategic or Co-development Partner
Description

Partnership for sustainable drug-device combination products. Ypsomed introduced YpsoMate in NetZero Program, a prefilled autoinjector designed to emit fewer greenhouse gas emissions. PCI collaborates on sustainable packaging solutions for injection devices. PCI helps clients evaluate, test, and launch eco-friendly packaging solutions for drug-device combination products.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swiss CDMO specializing in API production, oral solid dose drug products, and sterile fill-finish. Comparable to PCI on integrated small-molecule CDMO services and European footprint.

2Recipharm
TypeDirect peer
Description

European-headquartered CDMO offering sterile fill-finish, oral solids, biologics, and advanced delivery services. Closely comparable in scale, sterile focus, and integrated service model.

TypeBroad incumbent
Description

Swiss-headquartered CDMO leader with deep capabilities in API manufacturing, biologics, cell and gene therapy, and drug product services. Highly comparable integrated offering, materially larger, and a benchmark for PCI's biologics expansion.

TypeDirect peer
Description

Global CDMO offering development, manufacturing, and packaging services across sterile injectables, oral solids, and biologics; now owned by Novo Holdings. Directly comparable to PCI in integrated CDMO scope, though larger and more biologics-weighted.

TypeBroad incumbent
Description

Operates one of the largest global CDMO networks (formerly Patheon) across small molecules, biologics, sterile fill-finish, and clinical supply services. Comparable to PCI across essentially all service lines but with greater scale and parent-company resources.

TypeDirect peer
Description

European CDMO with strong capabilities in oral solids, sterile liquids, and packaging for pharma and consumer health. Similar mid-tier scale to PCI with overlapping sterile and packaging capabilities.

TypeDirect peer
Description

Northern Ireland-headquartered CDMO offering pharmaceutical development, clinical trial supply, commercial manufacturing, and packaging services. Directly comparable to PCI across both sterile and non-sterile service lines.

TypeDirect peer
Description

Chinese-headquartered integrated CDMO providing API manufacturing, drug product development, and commercial manufacturing across small molecules and biologics. Comparable to PCI on integrated development-through-commercial scope, though geography-anchored in Asia.

TypeDirect peer
Description

Large-scale biologics CDMO offering contract manufacturing, development services, and aseptic fill-finish. Directly comparable for the biologics segment of PCI's sterile services portfolio.

TypeOthers
Description

Swiss drug-device combination product manufacturer (auto-injectors, pen injectors). Listed as a strategic partner of PCI for sustainable injection devices rather than a direct competitor; included to highlight the drug-device combination adjacency rather than core CDMO competition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries9 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PCI Pharma Services

Pharmaceutical CDMO Servicespci.com

PCI Pharma Services is a privately held global CDMO providing integrated end-to-end drug development, manufacturing, and packaging services to pharmaceutical and biotechnology companies across 38 GMP facilities in seven countries, supported by the pci|bridge™ digital supply chain platform.

What PCI Pharma Services does

PCI Pharma Services is a privately held global Contract Development and Manufacturing Organization (CDMO) founded in 1972 and headquartered in Philadelphia, Pennsylvania. Operating under the legal entity Packaging Coordinators, Inc., the company provides integrated end-to-end drug development, manufacturing, and packaging services to pharmaceutical and biotechnology companies and clinical trial sponsors. Its service portfolio spans sterile and non-sterile drug development, lyophilization, fill-finish, prefilled syringe services, high-potency compound handling, biologics packaging, clinical trial supply chain management, cold chain logistics, commercial packaging, and advanced drug-device combination product assembly.

The company operates 38 GMP-compliant facilities across 30 sites in seven countries (United States, Canada, United Kingdom, Ireland, Germany, Spain, and Australia), supported by more than 8,000 employees. PCI's technology layer centers on the pci|bridge™ digital supply chain platform, which provides clients with real-time visibility into project status, inventory, documentation, and Qualified Person lot release workflows, integrated with DocuSign and Smartsheet. The platform is anchored by validated quality systems including MasterControl, LIMS, and electronic batch records. Supporting offerings include clinicalSMART™ for clinical supply project management, Activ-Blister™ for clinical trial blister packaging, and SpeedSolutions™ for accelerated commercialization.

PCI generates revenue through professional services engagements — long-term development, manufacturing, and packaging contracts with pharma and biotech clients — priced on a quote/contract basis per project. Go-to-market is direct enterprise field sales targeting pharmaceutical and biotech decision-makers, supported by industry conference participation, content marketing, and ESG-driven thought leadership. The company has grown substantially through acquisitions, completing five notable deals between 2017 and 2023 (LSNE, Penn Pharmaceutical Services, Sherpa Clinical Packaging, Pharmaceutical Packaging Professionals, and Millmount Healthcare), and has been recognized with multiple industry awards including 2025 CDMO Leadership Awards for Small Molecule and Biologics categories and consecutive EcoVadis Bronze Medals for sustainability performance.

PCI Pharma Services firmographics

Firmographics
Name
PCI Pharma Services
Legal name
Packaging Coordinators, Inc.
Website
https://pci.com
Company type
Private
Founded year
1972
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
PCI Pharma Services is a privately held global CDMO providing integrated end-to-end drug development, manufacturing, and packaging services to pharmaceutical and biotechnology companies across 38 GMP facilities in seven countries, supported by the pci|bridge™ digital supply chain platform.
Ownership category
akta.pro rank

PCI Pharma Services industry classification

Industry
Product category
Pharmaceutical CDMO Services
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Contract pharmaceutical manufacturing
  • Clinical trial supply services
  • Sterile fill-finish
  • Pharmaceutical packaging services
  • Drug-device combination products

Where PCI Pharma Services is headquartered

Location

Headquarters

HQ city
Philadelphia, PA
HQ country
United States
HQ region
North America

Offices15 records

Markets served

PCI Pharma Services business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

  1. Development & Manufacturing Services: Comprehensive drug development and manufacturing services including sterile and non-sterile manufacturing, lyophilization, fill-finish, prefilled syringe services, high-potency drug development and manufacturing, and oral targeted therapies.
  2. Clinical Trial Services: End-to-end clinical trial supply services including temperature controlled packaging, cold chain logistics, clinical storage and distribution, packaging design and development, and returns management.
  3. Commercial Packaging Technology: Commercial packaging services for both sterile and non-sterile products including standard and specialty dosage forms, serialization, compliance packaging, and launch support.
  4. Advanced Drug Delivery & Drug-Device Combination Products: Specialized services for drug-device combination products including prefilled syringes, advanced delivery systems, and combination product assembly and packaging.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

PCI Pharma Services product offering

Product offering

Core offering

PCI Pharma Services is a global contract development and manufacturing organization (CDMO) providing integrated end-to-end drug development, manufacturing, and packaging solutions for pharmaceutical and biotech clients. Services span sterile and non-sterile development and manufacturing, clinical trial supply chain services, commercial packaging technology, advanced drug delivery, and drug-device combination products, delivered through 38 GMP facilities across 7 countries.

Product overview

PCI Pharma Services is a global Contract Development and Manufacturing Organization (CDMO) providing integrated end-to-end drug development, manufacturing, and packaging solutions. The company operates two primary service categories: Sterile Services and Non-Sterile Services, each encompassing Development & Manufacturing, Clinical Trial Services, and Commercial Packaging Technology. The portfolio is anchored by the pci | bridge™ digital supply chain management platform, which provides clients with real-time visibility and integrates with DocuSign and Smartsheet. Supporting offerings include clinicalSMART™ for clinical supply project management, Activ-Blister™ Solutions for patient compliance packaging, and SpeedSolutions™ for accelerated commercialization. PCI also employs validated systems including MasterControl and LIMS within its digital quality ecosystem to ensure compliance and operational precision.

Differentiator

Problem solved

Functional benefit

Brands

  • clinicalSMART: Clinical supply project management solution for clinical trials
  • SpeedSolutions
  • pci | bridge
  • Activ-Blister

Products and services

  • Sterile Services Integrated sterile pharmaceutical CDMO services spanning drug development and manufacturing, clinical trial services, advanced drug delivery, and commercial packaging technology for sterile pharmaceutical products. Capabilities include sterile fill-finish, lyophilization (cycle development, bulk, and fill-finish), prefilled syringe services, complex formulations, and drug-device combination product assembly. Targeted at pharmaceutical and biotech clients requiring sterile manufacturing and packaging for injectable, biologic, and high-potency products.
  • Non-Sterile Services Integrated non-sterile pharmaceutical CDMO services spanning drug development and manufacturing, clinical trial services, and commercial packaging technology for non-sterile pharmaceutical products. Targeted at pharmaceutical and biotech clients requiring oral solid dose, topical, and other non-sterile manufacturing and packaging services.
  • SpeedSolutions™ Integrated suite of speed-to-market solutions designed to accelerate drug development and commercialization timelines for pharmaceutical and biotech clients. Brings together PCI's capabilities across development, manufacturing, clinical supply, and commercial packaging under a unified accelerated timeline approach.
  • pci | bridge™ Digital Supply Chain Platform Client-facing digital supply chain management platform connecting clients to critical operational data with real-time visibility into project status, inventory movement, and documentation workflows across clinical development through commercial launch. Features include customizable KPI dashboards, real-time inventory data, configurable reports, secure document sharing via DocuSign, automated QP lot release workflows, protocol spend tracking, and commercial forecast submission. Sold as part of PCI's CDMO service engagement for pharmaceutical and biotech clients.
  • clinicalSMART™ Clinical Supply Project Management Clinical supply project management service solution for tracking and managing clinical trial logistics, packaging, and distribution activities. Targeted at pharmaceutical and biotech sponsors running clinical trials who require integrated supply chain visibility and project coordination.
  • Activ-Blister™ Solutions Specialized blister packaging solutions for clinical trials, designed for patient compliance and adherence packaging. Targeted at pharmaceutical and biotech sponsors running clinical trials requiring patient-centric packaging to support medication adherence.

Quantifiable outcome

  • More than 90 successful product launches per year
  • +2 more outcomes

Companies that use PCI Pharma Services

Customer profile

Segments3 records

Ideal customer profiles3 records

PCI Pharma Services technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature4 records

PCI Pharma Services partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • YpsomedsignificantStrategic or Co-development PartnerPartnership for sustainable drug-device combination products. Ypsomed introduced YpsoMate in NetZero Program, a prefilled autoinjector designed to emit fewer greenhouse gas emissions. PCI collaborates on sustainable packaging solutions for injection devices. PCI helps clients evaluate, test, and launch eco-friendly packaging solutions for drug-device combination products.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

PCI Pharma Services competitors and assessment

Company assessment

Direct peers

  • Siegfried Holding: Swiss CDMO specializing in API production, oral solid dose drug products, and sterile fill-finish. Comparable to PCI on integrated small-molecule CDMO services and European footprint.
  • Recipharm: European-headquartered CDMO offering sterile fill-finish, oral solids, biologics, and advanced delivery services. Closely comparable in scale, sterile focus, and integrated service model.
  • Catalent: Global CDMO offering development, manufacturing, and packaging services across sterile injectables, oral solids, and biologics; now owned by Novo Holdings. Directly comparable to PCI in integrated CDMO scope, though larger and more biologics-weighted.
  • Aenova: European CDMO with strong capabilities in oral solids, sterile liquids, and packaging for pharma and consumer health. Similar mid-tier scale to PCI with overlapping sterile and packaging capabilities.
  • Almac Group: Northern Ireland-headquartered CDMO offering pharmaceutical development, clinical trial supply, commercial manufacturing, and packaging services. Directly comparable to PCI across both sterile and non-sterile service lines.
  • WuXi STA (WuXi AppTec): Chinese-headquartered integrated CDMO providing API manufacturing, drug product development, and commercial manufacturing across small molecules and biologics. Comparable to PCI on integrated development-through-commercial scope, though geography-anchored in Asia.
  • Samsung Biologics: Large-scale biologics CDMO offering contract manufacturing, development services, and aseptic fill-finish. Directly comparable for the biologics segment of PCI's sterile services portfolio.

Broad incumbents

  • Lonza: Swiss-headquartered CDMO leader with deep capabilities in API manufacturing, biologics, cell and gene therapy, and drug product services. Highly comparable integrated offering, materially larger, and a benchmark for PCI's biologics expansion.
  • Thermo Fisher Scientific (Patheon): Operates one of the largest global CDMO networks (formerly Patheon) across small molecules, biologics, sterile fill-finish, and clinical supply services. Comparable to PCI across essentially all service lines but with greater scale and parent-company resources.

Others

  • Yposomed (as a partner, not peer): Swiss drug-device combination product manufacturer (auto-injectors, pen injectors). Listed as a strategic partner of PCI for sustainable injection devices rather than a direct competitor; included to highlight the drug-device combination adjacency rather than core CDMO competition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

PCI Pharma Services social profiles

Digital presence

PCI Pharma Services compliance and trust

Trust signal

Compliance2 records

PCI Pharma Services financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PCI Pharma Services leadership team

Management profile

Number of profiles

Profiles4 records

PCI Pharma Services subsidiaries and ownership

Company hierarchy

Subsidiaries9 records

PCI Pharma Services funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PCI Pharma Services M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PCI Pharma Services

What does PCI Pharma Services do?

PCI Pharma Services is a global contract development and manufacturing organization (CDMO) providing integrated end-to-end drug development, manufacturing, and packaging solutions for pharmaceutical and biotech clients. Services span sterile and non-sterile development and manufacturing, clinical trial supply chain services, commercial packaging technology, advanced drug delivery, and drug-device combination products, delivered through 38 GMP facilities across 7 countries.

Is PCI Pharma Services a public or private company?

PCI Pharma Services is a private company. It is classified as unknown and is currently operating.

When was PCI Pharma Services founded?

PCI Pharma Services was founded in 1972. It employs 5,001 to 10,000 people.

Where is PCI Pharma Services based?

PCI Pharma Services is headquartered in Philadelphia, PA, United States, in the North America region.

How does PCI Pharma Services make money?

Four revenue lines are on record. Development & Manufacturing Services are the primary driver. The others are clinical Trial Services, commercial Packaging Technology and advanced Drug Delivery & Drug-Device Combination Products.

Who are PCI Pharma Services's main competitors?

Direct peers on record are Siegfried Holding, Recipharm, Catalent, Aenova, Almac Group, WuXi STA (WuXi AppTec) and Samsung Biologics. Broad incumbents are Lonza and Thermo Fisher Scientific (Patheon). Yposomed (as a partner, not peer) is listed as an others.

Does PCI Pharma Services have an API?

No public API is recorded for PCI Pharma Services.

What industry is PCI Pharma Services in?

PCI Pharma Services's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Telegraph‘My son died aged 29 but his employer won’t pay out his £140k death benefit’A reader's son died of cancer at 29, and his employer PCI Pharma Services delayed his death-in-service payout for over a year. The payout was £120,660.96, and after intervention, the family received the money plus a £5,000 goodwill offer.AETOSWirePCI Pharma Services Announces New Sterile Fill-Finish Capabilities Now Available in Melbourne and San DiegoPCI Pharma Services activated three new automated sterile fill-finish machines at its San Diego and Melbourne facilities. The equipment, from Cytiva, fills sterile medications into vials and syringes for small-to-mid scale needs, aiming to reduce turnaround times and address global capacity shortages.AETOSWireAldena Therapeutics Selects PCI Pharma Services to Manufacture and Distribute Innovative Investigational Treatment for Dermatological DiseasesAldena Therapeutics selected PCI Pharma Services to manufacture and distribute ALD-102, an siRNA-based injectable for dermatological conditions, at PCI's San Diego facility. The treatment is in preclinical trials and represents Aldena's most advanced therapy. PCI's integrated sterile fill-finish capabilities support clinical trial supply.AETOSWireLeading CDMO PCI Pharma Services Releases Inaugural Comprehensive ESG ReportPCI Pharma Services released its first ESG report covering 2021-2023, outlining targets for emissions, water, waste, and DEI. The report includes a Double Materiality Assessment showing stakeholder alignment, and sets goals like 40% emissions cut by 2030 and net-zero by 2045.AETOSWirePCI Pharma Services’ Bedford, New Hampshire Location Successfully Completes International Coalition of Medicines Regulatory Authorities InspectionPCI Pharma Services completed the ICMRA inspection of its Bedford, New Hampshire campus, becoming the first CDMO to undergo the multi-agency process. The inspection involved two agencies onsite and five virtually, aiming to abbreviate regulatory approvals. PCI recently invested over $100 million in infrastructure at the site.AETOSWirePCI Pharma Services Invests Over $365 Million in EU, US Facilities for Clinical and Commercial Supply of Advanced Drug Delivery and Drug-Device Combination ProductsPCI Pharma Services is investing over $365 million in new and expanded facilities in the EU and US for clinical and commercial-scale assembly and packaging of advanced drug delivery and drug-device combination products. The investments include a 545,000-square-foot expansion in Rockford, Illinois, and new facilities in Ireland, with operations expected to commence in 2024-2025.AETOSWirePCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto AltheaPCI Pharma Services is acquiring an entire equity stake in US-based sterile fill-finish CDMO Ajinomoto Althea, a 100% subsidiary of Ajinomoto Co., with completion scheduled for May 2025. The deal gives PCI its first North American manufacturing location for prefilled syringes and high-potent ADCs, complementing its global sterile fill-finish capabilities.AETOSWirePart of $1 Billion Investment Strategy, PCI Pharma Services Completes Acquisition of Ajinomoto Althea, Enhancing US Drug Product Manufacturing for Aseptic Filling of Prefilled Syringes & CartridgesPCI Pharma Services completed its acquisition of Ajinomoto Althea, a US sterile fill-finish CDMO, to enhance its aseptic filling of prefilled syringes and cartridges. The deal adds high-potent vial filling and lyophilization, positioning PCI among US CDMOs capable of filling antibody-drug conjugates. PCI's broader investment plan includes new facilities in the US and Europe, with GMP readiness in 2025.AETOSWirePCI Pharma Services Enters Next Phase of Growth With Strategic Investment from Bain Capital, Kohlberg, and MubadalaPCI Pharma Services announced a strategic investment co-led by Bain Capital and Kohlberg, with Mubadala reinvesting. Financial terms were not disclosed. The company will focus on organic and inorganic growth, including expanding sterile fill-finish and manufacturing capacity.LinkedInPCI Pharma ServicesPCI Pharma Services is promoting its digital transformation and supply chain capabilities through a series of webinars, industry articles, and partnership highlights. The company emphasizes the deployment of its pci | bridge™ platform for real-time visibility and discusses strategies for mitigating tariff impacts on pharmaceutical manufacturing. Additionally, PCI highlighted its collaboration with Alnylam Pharmaceuticals to support patient-centric therapies.